An estimated 1 billion people between the ages of 30 and 69 across the globe suffer from sleep apnea, particularly ...

People whose sleep apnea changes dramatically from night to night are 30% more likely to have a heart attack, stroke, or ...

Nearly 30 million adults in the U.S. have obstructive sleep apnea (OSA)—and many don't even know it. If you've been waking up ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...

Study finds people with severe sleep apnea face 71% higher risk of heart events, plus greater chances of obesity, diabetes, ...

People with obstructive sleep apnea often snore loudly, wake up frequently during the night, and feel very tired during the ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

February was heart month, and this is the fourth column in a series about the primary risk factors for heart attacks. Sleep apnea refers to periodic absence of breathing during sleep. There are two ...

Combining supplemental oxygen with mandibular advancement device (MAD) therapy significantly reduced obstructive sleep apnea (OSA) severity compared with sham treatment and offered a 14% greater ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Getty Images Sleep ...

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep. The ...

Zepbound (tirzepatide) is a brand-name injection prescribed for treating sleep apnea. This article covers topics such as side effects, dosage, and how Zepbound works. Zepbound is available in ...